Luca Bertolaccini: New Diagnostic Category for Grade 3 Lung Carcinoids
Luca Bertolaccini/LinkedIn

Luca Bertolaccini: New Diagnostic Category for Grade 3 Lung Carcinoids

Luca Bertolaccini, Thoracic Surgeon at IEO – European Institute of Oncology, shared on LinkedIn

“What should we call a lung tumor that looks like a well-differentiated carcinoid but has more than 10 mitoses per 2 mm²?

Under the current WHO thoracic classification, these rare tumors fall into the category of large cell neuroendocrine carcinoma. In the JTO, the International Association for the Study of Lung Cancer Pathology Committee proposes a different diagnosis: grade 3 lung carcinoid.

The authors examined 28 resected tumors from nine institutions in six countries. Mitotic counts ranged from 11 to 30 per 2 mm². All nine tumors that underwent sequencing had wild-type RB1 and TP53, with molecular findings consistent with lung carcinoids. Yet recurrence-free and overall survival were shorter in the study cohort than in the comparison groups of 117 typical and 52 atypical carcinoids.

As a surgeon, I think of the patient who asks at the first postoperative visit, ‘How likely is this to come back?‘ I would be cautious about quoting recurrence estimates from atypical carcinoid series when the resection specimen shows this degree of proliferation. These 28 cases support recognizing a distinct group. Estimating an individual patient’s risk within that group will require larger cohorts.

Title: Grade 3 Lung Carcinoids/NETs: The IASLC Pathology Committee Study with Proposal of a New Diagnostic Category

Authors: Natasha Rekhtman, Matthew G. Hanna, Paul Hofman, Mari Mino-Kenudson, Philippe Joubert, Mauro Papotti, Lynette M. Sholl, Hyo Sup Shim, Yuchen Han, Véronique Hofman, Yin P. Hung, Marina K. Baine, Rania G. Aly, Deepali Jain, Teodora Radonic, Anjali Saqi, Mary Beth Beasley, Jin-Haeng Chung, Wendy Cooper, Fred R. Hirsch, Keith Kerr, Sylvie Lantuejoul, Daisuke Matsubara, Noriko Motoi, Andrew G. Nicholson, William D. Travis, Jan von der Thüsen, Yasushi Yatabe, Anja C. Roden.

Read the study in the Journal of Thoracic Oncology.”

To which, International Association for the Study of Lung Cancer (IASLC), added:

“IASLC Communications Committee member Luca Bertolaccini shares his clinical perspective on new research from the IASLC Pathology Committee published in the Journal of Thoracic Oncology (JTO), exploring why recognizing grade 3 lung carcinoids as a distinct classification could matter for patient prognosis and care.”

You can also read:

Beyond Tumor Stage: Nature Cancer Study Maps the Hidden Cellular Drivers of Lung Cancer Metastasis

Luca Bertolaccini: New Diagnostic Category for Grade 3 Lung Carcinoids